依普利酮治疗高血压的安全性和高效性

Safety and effectiveness in treating high blood pressure:

The safety and effectiveness of eplerenone alone and in combination with other antihypertensive drugs were evaluated in 3091 patients with hypertension. 46% of the subjects were female, 14% were black, and 22% were elderly. Subjects with elevated baseline serum potassium (>5 mmol/L) and elevated baseline serum creatinine (>1.5 mg/dL in men and >1.3 mg/dL in women) were excluded from the study.

Two fixed-dose, placebo-controlled, 8- to 12-week monotherapy studies were conducted to evaluate the antihypertensive efficacy of eplerenone in patients with baseline diastolic blood pressure of 95 to 114 mmHg. In both studies, 61 patients were randomized to the eplerenone group and 140 patients were randomized to the placebo group. Patients receive 25 to 400 mg of eplerenone once or twice a day.

Patients treated with 50 to 200 mg of eplerenone per day had significant reductions in systolic and diastolic blood pressure. Compared with the placebo group, systolic blood pressure was reduced by 6 to 13 mmHg, and diastolic blood pressure was reduced by 3 to 7 mmHg.

In these studies, the analysis of 24-hour ABPM data showed that eplerenone once or twice a day can maintain the antihypertensive effect throughout the entire medication cycle, and eplerenone 50 mg twice a day has a better antihypertensive effect than once a day.

The antihypertensive effect can appear within 2 weeks of taking the medicine. Eplerenone can be used in combination with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, calcium antagonists, alpha-blockers, and hydrochlorothiazide. And the average heart rate did not change significantly in those who took the medicine together. There were also no effects of eplerenone on heart rate, QRS interval, PR interval, or QT interval.

Recommended related hot articles: /newsDetail/81692.html